Thyroid cancer: who works on it

One card per institution. Pick a target or a country to narrow the list.

• All targets
• BRAF 15
• RET 8
• PI3K 0
• TP53 0
• TERT 0
• MAPK 1
• GLP-1 1
• AKT 0
• PTEN 0
• STAT3 0
• mTOR 0
• NTRK 2
• PD-1 5
• RAS 1
• ERK 0
• MEK 1
• PSMA 1
• ALK 1
• EGFR 3
• VEGF 2
• PD-L1 0
• JAK 0
• KRAS 1
• CTNNB1 0
• NRAS 2
• NRF2 0
• PPAR 0
• TROP2 3
• AMPK 0
• DLL3 2
• HIF-1 0
• PIK3CA 0
• ABL1 0
• DPP-4 0
• IL-6 1
• METTL3 0
• TNF 0
• YAP 0
• AXL 1
• EZH2 0
• FGFR 0
• JNK 0
• MET 1
• MYC 0
• PKM2 0
• ROS1 1
• SGLT2 0
• STING 0
• ATM 0
• BRCA1 0
• BRCA2 0
• BRD4 0
• CDKN2A 0
• CGRP 0
• CTLA-4 0
• CXCR4 0
• FAK 0
• GPX4 0
• HMGB1 0
• IDH 0

13 of 13+ institutions, ordered by recent publications and open trials. This is not a ranking of quality.

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• NIH NCI · F31

  Improving Efficacy of TSHR-CART by Targeting Suppressive Myeloid Cells

  Mayo Clinic Rochester· Rochester, United States· US$50,114 awarded in fiscal year 2026· until Jul 2029

• NIH NCI · P01

  ImpACT: Improving Treatment Strategies for Anaplastic Thyroid Cancer Through Integration of Novel Therapies and Assessment of Tumor Response

  University of Tx Md Anderson Can Ctr· Houston, United States· US$2,709,149 awarded in fiscal year 2026· until Aug 2031

• NIH NCI · R01

  MRI-based Active Bone Marrow Imaging and Segmentation for Patient-Specific Radiopharmaceutical Therapy Dosimetry

  University of Wisconsin-Madison· Madison, United States· US$530,194 awarded in fiscal year 2026· until Aug 2031

• NIH NCI · R01

  Structural and mechanistic studies of the RAS/RAF MAPkinase pathway

  Dana-Farber Cancer Inst· Boston, United States· US$657,443 awarded in fiscal year 2026· until Aug 2031

• NIH NCI · F31

  Investigating the mechanism and clinical utility of keratin switching in thyroid cancer

  Vanderbilt University· Nashville, United States· US$35,582 awarded in fiscal year 2026· until Aug 2029

• European Commission (Horizon Europe) · HORIZON-ERC

  ALK-driven cancers: a Portfolio of ONcoimmunoTherapies to achieve tumor Eradication (A-PONTE)

  Universita Degli Studi di Torino· Torino, Italy· EU contribution €2,497,392· until Dec 2030

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-GF

  Chemotherapy-induced Alopecia - Relief Managed by Engineered Silk (CARMESilk)

  Friedrich-Schiller-Universität Jena· Jena, Germany· EU contribution €401,232· until Sept 2028· 2 countries

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-CSA

  Innovating Thyroid Health with Genomics and Predictive Algorithms through Collaborative Excellence (InnoThyroGen)

  Sveuciliste U Splitu Medicinski Fakultet· Split, Croatia· EU contribution €4,937,275· until Dec 2028· 2 countries

8 of 77 running projects, newest first. Listed amounts together: US$45.6m + €7.8m.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Trials whose registry record says individual participant data (IPD) will be shared.

• Study Of Entrectinib (Rxdx-101) in Children and Adolescents With Locally Advanced Or Metastatic Solid Or Primary CNS Tumors And/Or Who Have No Satisfactory Treatment Options

  NCT02650401· Hoffmann-La Roche· Source

• Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)

  NCT02568267· Hoffmann-La Roche· Source

• A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements

  NCT03093116· Turning Point Therapeutics, Inc.· Source

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 24
• Organoids 6
• Mendelian Randomization Analysis 16
• CRISPR-Cas Systems 3
• Gene Expression Profiling 65
• Sequence Analysis, RNA 7
• Whole Genome Sequencing 1
• Exome Sequencing 7
• Proteomics 14
• Metabolomics 9
• Mass Spectrometry 7
• Flow Cytometry 6
• Immunohistochemistry 72
• Liquid Biopsy 9
• Circulating Tumor DNA 3
• Xenograft Model Antitumor Assays 57
• Positron-Emission Tomography 44
• Magnetic Resonance Imaging 18
• Machine Learning 72
• Deep Learning 44
• Cohort Studies 118
• Genome-Wide Association Study 16

• FPSA, a potential risk factor for thyroid nodules by gender: A cohort study in China.

  Int J Biol Markers, Oct 2026

• Radiofrequency versus microwave ablation for non-functioning benign thyroid nodules: a single-institution comparative cohort study.

  Endocrine, Oct 2026

• Second primary malignancy risk following radioactive iodine therapy for thyroid cancer: a population-based matched cohort study in Taiwan.

  Eur J Endocrinol, Oct 2026

• Expanding the Molecular Data of DICER1-Related Tumor Predisposition: Novel Germline Variants in an Argentine Pediatric Cohort.

  Hum Mutat, Sept 2026

• Validation of a thyroid malignancy risk calculator in a Portuguese cohort.

  Endocrine, Sept 2026

• Beyond Tumor Diameter: Exploratory Cohort-Derived Calcitonin Secretory Categories and Invasive Pathology in Medullary Thyroid Carcinoma.

  Curr Oncol, Sept 2026

• Sex and Mortality Among Patients with Papillary Thyroid Cancer.

  JAMA Netw Open, Sept 2026

• Cancer Risk Among Young Adults With Clinically Diagnosed Fatty Liver Disease: A Nationwide Cohort Study in South Korea.

  Cancer Med, Sept 2026

• Radiation Risk of Screening-Detected Diffuse Goiter in a Belarusian Cohort Exposed as Children or Adolescents to Iodine-131 after Chernobyl.

  Cancer Epidemiol Biomarkers Prev, Sept 2026

• APOC1-Associated VLDL-Pathway Dysregulation in Papillary Thyroid Carcinoma: A Reproducible Cross-Cohort Transcriptomic Signature Associated With the Diagnostic-to-Treatment Interval.

  Chem Biol Drug Des, Sept 2026

See which targets of this disease your abstract mentions, and go to the people working on them.